Ardelyx, Inc. (ARDX)
| Market Cap | 1.44B |
| Revenue (ttm) | 134.27M |
| Net Income (ttm) | -26.57M |
| Shares Out | 232.14M |
| EPS (ttm) | -0.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,697,984 |
| Open | 6.41 |
| Previous Close | 6.42 |
| Day's Range | 6.18 - 6.42 |
| 52-Week Range | 2.53 - 6.75 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 9.58 (+54.52%) |
| Earnings Date | Oct 31, 2023 |
About ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatm... [Read more]
Financial Performance
In 2022, Ardelyx's revenue was $52.16 million, an increase of 416.57% compared to the previous year's $10.10 million. Losses were -$67.21 million, -57.51% less than in 2021.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price forecast is $9.58, which is an increase of 54.52% from the latest price.
News
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx Announces Departure of Board Member
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx to Participate at the Jefferies London Healthcare Conference
WALTHAM, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
Continued successful launch of IBSRELA, with Q3 net sales revenue of $22.3 million; Company currently expects 2023 full year IBSRELA U.S. net sales revenue to be $76 to $78 million
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
WALTHAM, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
WALTHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx wins long battle for FDA approval of kidney-disease treatment
Ardelyx Inc. ARDX, -0.58% on Tuesday won its long fight for U.S. regulatory approval of a treatment designed to help patients with chronic kidney disease.
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
Additional non-dilutive capital extends runway to support the launch of XPHOZAH® (tenapanor) and continued commercial investment into IBSRELA® (tenapanor) in the U.S. Additional non-dilutive capital e...
US FDA approves Ardelyx's kidney disease-related drug
The U.S. Food and Drug Administration (FDA) has approved Ardelyx's drug to treat high phosphate levels in patients with chronic kidney disease (CKD), the company said on Tuesday, more than two years a...
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
XPHOZAH has been approved to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who a...
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class me...
Ardelyx shares climb as kidney-disease drug gets green light from Japanese regulators
Ardelyx Inc. shares ARDX, +7.92% gained 6% premarket on Monday after the company announced that its partner Kyowa Kirin Co. Ltd. received Japanese regulatory approval for tenapanor for patients with c...
Tenapanor for Hyperphosphatemia Approved in Japan
Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa Kirin in milestone and license amendment payments and $5 million from HealthCare Royalty Part...
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
Continued successful launch of IBSRELA, with Q 2 net sales revenue of $18.3 million ; Company currently expects 2023 full year IBSRELA net sales revenue to be $72 to $77 million
Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
WALTHAM, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
WALTHAM, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class med...
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma Acceptance of NDA Submission triggers as $2 million milestone payment to Ardelyx by Fosun Pharma
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
WALTHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medi...
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medi...
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million XPHOZAH New Drug Application resubmitted on April 17, 2023 Company ends Q1 with over $130 million in cash and investm...
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
WALTHAM, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medi...